Alcoholic Liver Disease Clinical Trial
Official title:
THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.
The study will be an experimental pre-post trial in which patients with ethanol related liver disease (both severe alcoholic hepatitis and decompensated ) admitted in our institute from Jun 2013-Dec 2014 will be enrolled in the study. Those on ryle's tube feeding would receive polymeric blenderized kitchen based liquid diet while those tolerating orally would receive soft/ solid diet as tolerated as per requirement. All the patients would receive same amount of calories i.e., 30-35 kcal/kg ideal body weight/ day and 1-1.2 gm/kg protein. 35-40% of non protein calorie would be provided as fats and rest of the calories will be provided as carbohydrates. All patients will be transfused 250ml of 20% intra lipid per day for 3 consecutive days, over and above the feed provided to them to be taken enterally (orally or through Ryle's Tube). Patients will undergo tests prior to infusion and 72 hours after infusion.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00708617 -
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
|
N/A | |
Completed |
NCT00990639 -
Effect of Candesartan in Alcoholic Liver Fibrosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04106518 -
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
|
||
Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Completed |
NCT01501162 -
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
|
Phase 4 | |
Recruiting |
NCT05895890 -
French National MICMAF Cohort
|
||
Completed |
NCT04557774 -
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
|
||
Recruiting |
NCT03267069 -
Evaluating Alcohol Use in Alcoholic Liver Disease
|
||
Recruiting |
NCT03295812 -
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
|
N/A | |
Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
Not yet recruiting |
NCT03503708 -
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
|
N/A | |
Completed |
NCT02796469 -
Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT02140294 -
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT03209791 -
Ethanol Induces Skeletal Muscle Autophagy
|
||
Recruiting |
NCT04736966 -
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
|
Phase 1 | |
Recruiting |
NCT04400604 -
Study of Alcohol-related Liver Disease in Europe
|
||
Completed |
NCT03402256 -
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
|
N/A | |
Completed |
NCT01711125 -
Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT03863730 -
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
|
N/A |